Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc. (BNO) priced its initial public offering on Dec 17, 2021 at $12.35 per ADS, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $89.2M. Evercore ISI was lead-left underwriter, joined by William Blair, Cantor and H.C. Wainwright. Latham & Watkins advised the company and Goodwin Procter and Herbert Smith Freehills advised the underwriters.

Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company developing allosteric ion channel modulators for serious central nervous system disorders. It works on the alpha-7 nicotinic acetylcholine receptor, an ion channel involved in emotional responses and cognitive performance.

Status

IPO

Ticker

BNO

Exchange

Nasdaq Global Market

Priced

Dec 17, 2021

IPO price

$12.35 per ADS

Market cap at IPO price

$89.2M

First filed

Nov 22, 2021

Underwriters

Evercore ISI, William Blair, Cantor and H.C. Wainwright

Company counsel

Latham & Watkins

Underwriters' counsel

Goodwin Procter and Herbert Smith Freehills

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.